Standard BioTools Inc.

11/19/2026 | Press release | Distributed by Public on 11/19/2026 16:02

Business Combination Prospectus (Form 425)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 19, 2026

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

Delaware
001-34180
77-0513190
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)

50 Milk Street, 10th Floor
Boston, Massachusetts 02109
(Address of principal executive offices and zip code)
(650) 266-6000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☒
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common stock, $0.001 par value per share
LAB
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As disclosed in Item 5.07 of this Current Report on Form 8-K, at the Special Meeting (as defined below), the stockholders of Standard BioTools Inc. (the "Company") voted to approve the Post-Closing Equity Incentive Plan and the Post-Closing ESPP, each as defined in the Company's definitive proxy statement/prospectus (the "Proxy Statement/Prospectus"), filed with the Securities and Exchange Commission (the "SEC") on October 21, 2026 pursuant to Rule 424(b)(3) and forming part of the Company's registration statement on Form S-4 (File No. 333-297560), which was declared effective by the SEC on October 21, 2026. The Post-Closing Equity Incentive Plan and the Post-Closing ESPP will become effective at the effective time of the Merger (as defined in the Proxy Statement/Prospectus) and are each contingent on the closing of the Merger.

The material features of the Post-Closing Equity Incentive Plan and the Post-Closing ESPP are set forth in the Proxy Statement/Prospectus. Those summaries and the foregoing descriptions are qualified in their entirety by reference to the complete text of the Post-Closing Equity Incentive Plan and the Post-Closing ESPP, copies of which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and incorporated in this Item 5.02 by reference.

Item 5.07.
Submission of Matters to a Vote of Security Holders.

On November 19, 2026, the Company held a virtual special meeting of stockholders (the "Special Meeting") to vote on the proposals identified in the Proxy Statement/Prospectus.

At the close of business on October 16, 2026, the record date for the Special Meeting, there were 394,711,296 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), issued and outstanding and entitled to vote at the Special Meeting. A total of 281,744,412 votes, or approximately 71.38% of the total voting power of the shares of the Company's capital stock issued and outstanding and entitled to vote at the Special Meeting, were present virtually or represented by proxy at the Special Meeting, constituting a quorum. The following proposals are described in detail in the Proxy Statement/Prospectus. The final voting results for each of the matters submitted to a vote of the Company's stockholders at the Special Meeting are set forth below:

1. Share Issuance Proposal. The proposal to approve the issuance of shares of Common Stock in connection with the Merger and in accordance with Nasdaq Listing Rules 5635(a) and 5635(b) was approved by the following votes:

Votes For
Votes Against
Abstentions
274,099,041
7,571,806
73,565
2. Charter Amendment Proposal. The proposal to approve an amendment to the Company's Eighth Amended and Restated Certificate of Incorporation, as amended, to (i) effect a reverse stock split of the Company's issued and outstanding Common Stock at a ratio in the range from 1-for-20 to 1-for-40, inclusive, with the final ratio to be mutually agreed to by the Company and Treeline Biosciences, Inc., and (ii) change the name of the Company to "Treeline Biosciences, Inc." was approved by the following votes:

Votes For
Votes Against
Abstentions
275,584,914
6,123,396
36,102

3. Post-Closing Equity Incentive Plan Proposal. The proposal to approve the Post-Closing Equity Incentive Plan, which will become effective at the effective time of the Merger and is contingent on the closing of the Merger, was approved by the following votes:

Votes For
Votes Against
Abstentions
207,381,782
57,483,106
16,879,524

4. Post-Closing ESPP Proposal. The proposal to approve the Post-Closing Employee Stock Purchase Plan (as defined in the Proxy Statement/Prospectus), which will become effective at the effective time of the Merger and is contingent on the closing of the Merger, was approved by the following votes:

Votes For
Votes Against
Abstentions
224,903,287
39,976,090
16,865,035
5. Advisory Compensation Proposal. The proposal to approve, on a nonbinding, advisory basis, the Transaction-Related Compensation (as defined in the Proxy Statement/Prospectus) was approved by the following votes:
Votes For
Votes Against
Abstentions
248,805,322
15,966,136
16,972,954

6. Element Mass Cytometry Divestiture Proposal. The proposal to approve the Element Mass Cytometry Divestiture (as defined in the Proxy Statement/Prospectus), which may be considered a sale of substantially all of the assets of the Company under Section 271 of the Delaware General Corporation Law, was approved by the following votes:

Votes For
Votes Against
Abstentions
276,299,544
5,336,020
108,848

7. Adjournment Proposal. The proposal to approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Share Issuance Proposal and/or the Charter Amendment Proposal if there are insufficient votes at the time of such adjournment to approve such proposals or to ensure that any supplement or amendment to the Proxy Statement/Prospectus is timely provided to the Company's stockholders was approved by the following votes:

Votes For
Votes Against
Abstentions
255,788,813
9,049,389
16,906,210

There were no broker non-votes with respect to any of the proposals.

Item 7.01.
Regulation FD Disclosure.

On November 19, 2026, the Company issued a press release announcing that its stockholders voted to approve all proposals at the Special Meeting. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference.

The information set forth in this Item 7.01 and in the attached Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01.
Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit No.
Description
10.1+
Post-Closing Equity Incentive Plan.
10.2+
Post-Closing ESPP.
99.1
Press Release, dated November 19, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).

+ Indicates management contract or compensatory plan or arrangement.

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
November 19, 2026
STANDARD BIOTOOLS INC.


By:
/s/ Alex Kim

Name:
Alex Kim

Title:
Chief Financial Officer

Standard BioTools Inc. published this content on November 19, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 19, 2026 at 22:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]